Theralase(R) Extends Warrants
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, has announced plans to extend the expiry date of 4.8 million share purchase warrants. The warrants, originally issued on June 30th, 2023, will be extended from June 30th, 2025, to June 30th, 2028.
The warrants remain exercisable at CAN $0.35 per share, with all other terms and conditions unchanged. This extension is pending final acceptance from the TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), una società farmaceutica in fase clinica specializzata in terapie attivate da luce, radiazioni, suoni e farmaci per il trattamento di cancro, batteri e virus, ha annunciato l'intenzione di prorogare la scadenza di 4,8 milioni di warrant per l'acquisto di azioni. I warrant, originariamente emessi il 30 giugno 2023, saranno estesi dalla data del 30 giugno 2025 al 30 giugno 2028.
I warrant restano esercitabili al prezzo di 0,35 dollari canadesi per azione, con tutte le altre condizioni invariate. Questa proroga è soggetta all'approvazione finale da parte della TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), una empresa farmacéutica en etapa clínica enfocada en terapias activadas por luz, radiación, sonido y fármacos para el tratamiento de cáncer, bacterias y virus, ha anunciado planes para extender la fecha de vencimiento de 4.8 millones de warrants para compra de acciones. Los warrants, emitidos originalmente el 30 de junio de 2023, serán extendidos desde el 30 de junio de 2025 hasta el 30 de junio de 2028.
Los warrants siguen siendo ejercitables a 0.35 dólares canadienses por acción, manteniéndose sin cambios todos los demás términos y condiciones. Esta extensión está pendiente de la aceptación final por parte de la TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF)는 암, 박테리아 및 바이러스 치료를 위한 빛, 방사선, 음파 및 약물 활성화 치료법에 중점을 둔 임상 단계 제약 회사로서, 480만 주의 주식 매수권 만기 연장 계획을 발표했습니다. 해당 매수권은 2023년 6월 30일에 최초 발행되었으며, 만기가 2025년 6월 30일에서 2028년 6월 30일로 연장됩니다.
매수권 행사가격은 주당 캐나다 달러 0.35로 유지되며, 기타 모든 조건은 변경되지 않습니다. 이 연장은 TSX 벤처 거래소의 최종 승인을 기다리고 있습니다.
Theralase Technologies (OTCQB : TLTFF), une entreprise pharmaceutique en phase clinique spécialisée dans les thérapies activées par la lumière, les radiations, le son et les médicaments pour le traitement du cancer, des bactéries et des virus, a annoncé son intention de prolonger la date d’expiration de 4,8 millions de bons de souscription d’actions. Ces bons, initialement émis le 30 juin 2023, verront leur échéance repoussée du 30 juin 2025 au 30 juin 2028.
Les bons restent exerçables au prix de 0,35 dollar canadien par action, toutes les autres conditions demeurant inchangées. Cette extension est soumise à l’approbation finale de la TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), ein pharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf licht-, strahlen-, schall- und medikamentenaktivierte Therapien zur Behandlung von Krebs, Bakterien und Viren spezialisiert hat, hat Pläne angekündigt, die Verfallsfrist von 4,8 Millionen Aktienkaufoptionsscheinen zu verlängern. Die ursprünglich am 30. Juni 2023 ausgegebenen Optionsscheine werden vom 30. Juni 2025 bis zum 30. Juni 2028 verlängert.
Die Optionsscheine bleiben zum Preis von 0,35 kanadischen Dollar pro Aktie ausübbar, alle anderen Bedingungen bleiben unverändert. Diese Verlängerung steht noch unter dem Vorbehalt der endgültigen Zustimmung der TSX Venture Exchange.
- None.
- Warrant extension could indicate company's challenge in achieving warrant exercise at current price levels
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 4,800,000 share purchase warrants ("Warrants") expiring June 30th, 2025 to June 30th, 2028.
The Warrants were issued on June 30th, 2023, pursuant to a private placement involving the issuance of 4,800,000 units of the Company. The Warrants are exercisable at $CAN 0.35 per share. All other terms and conditions of the Warrants will remain unchanged. The Warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257183
FAQ
What is the new expiry date for Theralase (TLTFF) warrants?
How many warrants are affected by Theralase's extension?
What is the exercise price of Theralase (TLTFF) warrants?
When were the Theralase warrants originally issued?
